Gene · 23308
Papers2,855
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,855
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters. | PLoS Pathog | 2024 | 38198521 | PubTator, text mining | PubMed |
| Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. | Cell Death Dis | 2024 | 38191571 | PubTator, text mining | PubMed |
| Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction. | Bioorg Med Chem Lett | 2024 | 38185345 | PubTator, text mining | PubMed |
| Comprehensive analysis of a tryptophan metabolism-related model in the prognostic prediction and immune status for clear cell renal carcinoma. | Eur J Med Res | 2024 | 38183155 | PubTator, text mining | PubMed |
| Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer. | Exp Mol Med | 2024 | 38177294 | PubTator, text mining | PubMed |
| Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases. | Oncoimmunology | 2024 | 38169917 | PubTator, text mining | PubMed |
| ICOSLG acts as an oncogene to promote glycolysis, proliferation, migration, and invasion in gastric cancer cells. | Arch Biochem Biophys | 2024 | 38081339 | PubTator, text mining | PubMed |
| BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms. | Int J Cancer | 2024 | 38078628 | PubTator, text mining | PubMed |
| Targeted therapies for lupus nephritis: Current perspectives and future directions. | Chin Med J (Engl) | 2024 | 38057972 | PubTator, text mining | PubMed |
| B7-H3/CD276 and small-cell lung cancer: What's new? | Transl Oncol | 2024 | 37865049 | PubTator, text mining | PubMed |
| Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma. | Blood | 2024 | 37847858 | PubTator, text mining | PubMed |
| The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside. | Transl Oncol | 2024 | 37844479 | PubTator, text mining | PubMed |
| CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer. | Biomol Biomed | 2024 | 37597212 | PubTator, text mining | PubMed |
| Endothelial cell provenance: an unclear role in transplant medicine. | Front Transplant | 2023 | 38993867 | PubTator, text mining | PubMed |
| The susceptibility of single nucleotide polymorphisms located within co-stimulatory pathways to systemic lupus erythematosus. | Front Immunol | 2023 | 38361527 | PubTator, text mining | PubMed |
| Enhanced CT-based radiomics model to predict natural killer cell infiltration and clinical prognosis in non-small cell lung cancer. | Front Immunol | 2023 | 38283362 | PubTator, text mining | PubMed |
| Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing. | Front Immunol | 2023 | 38283342 | PubTator, text mining | PubMed |
| Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential. | Med Rev (2021) | 2023 | 38282801 | PubTator, text mining | PubMed |
| Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift. | Front Immunol | 2023 | 38239354 | PubTator, text mining | PubMed |
| In vitro immune evaluation of adenoviral vector-based platform for infectious diseases. | BioTechnologia (Pozn) | 2023 | 38213479 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23308/papers?page=8